Clinical trials: Bone Marrow
Myelofibrosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary…
- Trial name
- NCT05371964
- Testing
- Imetelstat sodium, Ruxolitinib
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Geron Corporation
Lymphoma Nonhodgkin
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular…
- Trial name
- NCT04618081
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Celgene
Low and Int 1-risk Myelodysplastic Syndrome
Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
The primary purpose of this trial was is to assess the effect of treatment with deferasirox combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low- and int-1-risk myelodysplastic syndrome.
- Trial name
- NCT01868477
- Testing
- Deferasirox DFX, DT, Erythropoietin alpha, Deferasirox DFX, FCT
- Where
- 30 sites in Algeria, Argentina and 8 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Myelodysplastic Syndrome, MDS
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
This first-in-human, 3-stage, open-label study evaluated the safety and pharmacokinetics of ASTX727, as well as determined the dose for later stages.
- Trial name
- NCT02103478
- Testing
- ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination
- Where
- 17 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Subchondral Cysts, Subchondral Bone Edema
SCP Hip Outcomes Study
Post-market clinical outcomes study to collect data on the short- and long-term outcomes for subjects who are undergoing or have undergone the Subchondroplasty® (SCP®) Procedure in the hip in a standard clinical setting.
- Conditions
- Subchondral Cysts, Subchondral Bone Edema, Bone Marrow Edema, Insufficiency Fractures
- Trial name
- NCT03494660
- Testing
- Subchondroplasty Procedure with AccuFill
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- Zimmer Biomet
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003827
- Testing
- amifostine trihydrate, cytarabine, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ALZA
Hematologic Malignancy, Acute Myeloid Leukemia
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- NCT03795779
- Testing
- CLL1-CD33 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Aplastic Anemia
Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia
To evaluate the long-term efficacy and safety after the end of romiplostim treatment by observation [up to 5 years] of patients who were registered for Study 531-003/531-004 in immunosuppressive therapy-naïve patients with…
- Trial name
- NCT04870346
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage.
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- NCT01398462
- Testing
- CWP232291
- Where
- 5 sites in United States, South Korea
- Volunteers
- 69 people
- Sponsor
- JW Pharmaceutical
Anemia, Aplastic
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV)…
- Trial name
- NCT06991894
- Where
- United States
- Volunteers
- 2,517 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
This study is to evaluate efficacy and safety of Imatinib in two groups of patients; all patients should be diagnosed less than 3 months as chronic myeloid leukemia in a chronic phase.
- Trial name
- IDEAL (NCT02204722)
- Testing
- 600mg/day of Imatinib, 400mg/day of Imatinib
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Dong-A ST Co., Ltd.
Myelodysplastic Syndromes
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category…
- Trial name
- NCT03502668
- Testing
- ASTX727 LD, ASTX727 SD
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 160 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Breast Cancer
A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)
The purpose of this study is to evaluate incidence of grade 4 neutropenia in patients who have hepatic impairment and use the study medicine Palbociclib.This study is seeking participants: - treated with the study medicine…
- Trial name
- NCT05912933
- Where
- United States
- Volunteers
- 1,342 people
- Sponsor
- Pfizer
Myelofibrosis
Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.
This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or refractory of ruxolitinib treatment.
- Trial name
- NCT04851535
- Testing
- Jaktinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
The primary objective of this study is to determine the safety and tolerability of utilizing the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of advanced, previously treated myelodysplastic…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Anemia, Refractory, With Excess of Blasts
- Trial name
- NCT03175978
- Testing
- IGF/MTX
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- IGF Oncology, LLC
Aplastic Anemia
A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
The purpose of the study is to assess the efficacy and safety of PF-06462700 administered intravenously at 40 mg/kg/day for 4 days in Japanese participants with moderate and above aplastic anemia for making an approval…
- Trial name
- NCT04350606
- Testing
- PF-06462700
- Where
- 3 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Multiple Myeloma, Non-Hodgkin Lymphoma
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
To determine the maximum tolerated dose (MTD) of OPB-51602
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Trial name
- NCT01344876
- Testing
- OPB-51602
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Single Level Posterolateral Spinal Fusion
Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
The hypothesis is that Aastrom TRC autologous bone marrow tissue "grafts" can be safely used to promote bone healing as part of a single level posterolateral spine fusion surgical procedure.
- Trial name
- NCT00797550
- Testing
- Bone Repair Cells (BRCs), Autologous bone graft
- Volunteers
- 2 people
- Sponsor
- Vericel Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.